Comparative effectiveness of external-beam radiation approaches for prostate cancer

European Urology

Volumn 65, Issue 1, 2014, Pages 162-168

  Jacobs, Bruce L ^a   Zhang, Yun ^a   Skolarus, Ted A ^a,b   Wei, John T ^a,c   Montie, James E ^a   Miller, David C ^a   Hollenbeck, Brent K ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Complications; Intensity modulated radiotherapy; Prostate cancer; Radiation; Salvage therapy

Indexed keywords

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION INJURY; SALVAGE THERAPY; THREE DIMENSIONAL CONFORMAL THERAPY; COMPARATIVE STUDY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME;

EID: 84888854251     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.06.055     Document Type: Article

References (30)

1. R. Siegel, E. Ward, O. Brawley, and A. Jemal Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin 61 2011 212 236
2. D.C. Miller, S.B. Gruber, B.K. Hollenbeck, J.E. Montie, and J.T. Wei Incidence of initial local therapy among men with lower-risk prostate cancer in the United States J Natl Cancer Inst 98 2006 1134 1141
3. J. Staffurth Radiotherapy Development Board. A review of the clinical evidence for intensity-modulated radiotherapy Clin Oncol (R Coll Radiol) 22 2010 643 657
4. M.J. Zelefsky, E.J. Levin, and M. Hunt Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 70 2008 1124 1129
5. A.B. Jani, A. Su, and M.T. Milano Intensity-modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicity Urology 67 2006 147 151
6. S.A. Vora, W.W. Wong, S.E. Schild, G.A. Ezzell, and M.Y. Halyard Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 68 2007 1053 1058
7. A.W. Su, and A.B. Jani Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique Am J Clin Oncol 30 2007 215 219
8. P.A. Kupelian, C.A. Reddy, T.P. Carlson, K.A. Altsman, and T.R. Willoughby Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer Int J Radiat Oncol Biol Phys 53 2002 904 912
9. N.C. Sheets, G.H. Goldin, and A.M. Meyer Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer JAMA 307 2012 1611 1620
10. E.J. Hall, and C.S. Wuu Radiation-induced second cancers: the impact of 3D-CRT and IMRT Int J Radiat Oncol Biol Phys 56 2003 83 88
11. P.L. Nguyen, X. Gu, and S.R. Lipsitz Cost implications of the rapid adoption of newer technologies for treating prostate cancer J Clin Oncol 29 2011 1517 1524
12. S.F. Altekruse, C.L. Kosary, and M. Krapcho SEER cancer statistics review, 1975-2007 2010 National Cancer Institute Bethesda, MD
13. C.N. Klabunde, A.L. Potosky, J.M. Legler, and J.L. Warren Development of a comorbidity index using physician claims data J Clin Epidemiol 53 2000 1258 1267
14. J.E. Bekelman, N. Mitra, and J. Efstathiou Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer Int J Radiat Oncol Biol Phys 81 2011 e325 e334
15. L.I. Iezzoni, J. Daley, and T. Heeren Identifying complications of care using administrative data Med Care 32 1994 700 715
16. P.B. Bach, E. Guadagnoli, D. Schrag, N. Schussler, and J.L. Warren Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations Med Care 40 Suppl 2002 IV-19-25
17. J. Mohler, R.R. Bahnson, and B. Boston NCCN clinical practice guidelines in oncology: prostate cancer J Natl Compr Canc Netw 8 2010 162 200
18. A.V. Diez Roux, S.S. Merkin, and D. Arnett Neighborhood of residence and incidence of coronary heart disease N Engl J Med. 345 2001 99 106
19. B.L. Jacobs, Y. Zhang, T.A. Skolarus, and B.K. Hollenbeck Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse Health Aff (Millwood) 31 2012 750 759
20. P.C. Koper, J.C. Stroom, and W.L. van Putten Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study Int J Radiat Oncol Biol Phys 43 1999 727 734
21. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
22. Ottawa Hospital Research Institute. 3D-conformal radiation vs helical tomotherapy in prostate cancer [identifier NCT00326638 ]. Clinical trials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00326638?term= NCT+00326638&rank=1. Accessed November 7, 2011.
23. L. Collette, T. Burzykowski, and F.H. Schroder Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials Eur J Cancer 42 2006 1344 1350
24. V.B. Shahinian, Y.F. Kuo, J.L. Freeman, and J.S. Goodwin Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154 164
25. M.G. Sanda, R.L. Dunn, and J. Michalski Quality of life and satisfaction with outcome among prostate-cancer survivors N Engl J Med 358 2008 1250 1261
26. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
27. J.P. Newhouse Medical care costs: how much welfare loss? J Econ Perspect 6 1992 3 21
28. M.K. Tollefson, M.T. Gettman, R.J. Karnes, and I. Frank Administrative data sets are inaccurate for assessing functional outcomes after radical prostatectomy J Urol 185 2011 1686 1690
29. A.L. Potosky, J.L. Warren, E.R. Riedel, C.N. Klabunde, C.C. Earle, and C.B. Begg Measuring complications of cancer treatment using the SEER-Medicare data Med Care 40 Suppl 2002 IV-62-8
30. L.A.G. Ries, M. Krapcho, and D.G. Stinchcomb SEER cancer statistics review, 1975-2005 2008 National Cancer Institute Bethesda, MD